A nanoemulsified formulation of dolutegravir and epigallocatechin gallate inhibits HIV‐1 replication in cellular models

Abstract

Nanotechnology offers promising avenues for enhancing drug delivery systems, particularly in HIV‐1 treatment. This study investigates a nanoemulsified formulation combining epigallocatechin gallate (EGCG) with dolutegravir (DTG) for managing HIV‐1 infection. The combinatorial interaction between EGCG and DTG was explored through cellular, enzymatic, and molecular studies. In vitro assays demonstrated the potential of a dual drug‐loaded nanoemulsion, NE‐DTG‐EGCG, in inhibiting HIV‐1 replication, with EGCG serving as a supplementary treatment containing DTG. In silico molecular interaction studies highlighted EGCG's multifaceted inhibitory potential against HIV‐1 integrase and reverse transcriptase enzymes. Further investigations are needed to validate the formulation's efficacy across diverse contexts. Overall, by integrating nanotechnology into drug delivery systems, this study represents a significant advancement in managing HIV‐1 infection.